Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of...
-
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
-
New York, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the agenda including tracks and chairs for the 2026 MDA Clinical & Scientific Conference...
-
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval and Positive Interim Clinical Data for LX2006 in FA Cardiomyopathy
-
Paris, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Builds on positive top-line data from first cohort demonstrating significant reduction in urinary incontinence episodes Paris, France, October 6, 2025 –...
-
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
-
New York, July 30, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), leader and innovator of the largest global gathering of the neuromuscular disease community, announced today...
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
-
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
-
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia